Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cordis Launches Low-Profile Incraft AAA Stent Graft In Europe And Canada

This article was originally published in The Gray Sheet

Executive Summary

The J&J division has been talking-up Incraft as a potentially major innovation in the treatment abdominal aortic aneurysms for several years.

You may also be interested in...



Global Device Approvals, Weekly Snapshot: New Shoulder Component, AAA Graft

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. Newly added devices include a new LimaCorporate should component, US approval of the Incraft aneurysm stent graft and a first-in-class newborn-screening diagnostic.

EVAR Update: Competitors Stake Their Ground In A High-Growth Space

The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.

J&J Spotlights AAA Device, Thermocool Extensions During Analyst Meeting

Johnson & Johnson is looking to the Nevo sirolimus-eluting stent and entry into fast-growing endovascular device segments, such as the abdominal aortic aneurysm market, to restore growth in its struggling Cordis unit

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT033298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel